Moderna to seek parity for RSV shot as rivals lead in market

seekingalpha05-03

With its Q1 2024 financials on Thursday, Moderna (NASDAQ:MRNA) highlighted its upcoming RSV vaccine, noting that the company expects U.S. regulators to recommend its messenger-RNA-based shot on par ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432993572?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1730228397/image_1730228397.jpg","is_english":true,"pubTime":"2024-05-03 01:48","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2432993572","market":"us","top_or_hot":-1,"title":"Moderna to seek parity for RSV shot as rivals lead in market","media":"seekingalpha","content":"<div>\n<p>With its Q1 2024 financials on Thursday, Moderna (NASDAQ:MRNA) highlighted its upcoming RSV vaccine, noting that the company expects U.S. regulators to recommend its messenger-RNA-based shot on par ...</p>\n\n<a href=\"https://seekingalpha.com/news/4099014-moderna-to-seek-parity-for-rsv-shot-as-rivals-lead-in-market\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna to seek parity for RSV shot as rivals lead in market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna to seek parity for RSV shot as rivals lead in market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-03 01:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4099014-moderna-to-seek-parity-for-rsv-shot-as-rivals-lead-in-market><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>With its Q1 2024 financials on Thursday, Moderna (NASDAQ:MRNA) highlighted its upcoming RSV vaccine, noting that the company expects U.S. regulators to recommend its messenger-RNA-based shot on par ...</p>\n\n<a href=\"https://seekingalpha.com/news/4099014-moderna-to-seek-parity-for-rsv-shot-as-rivals-lead-in-market\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://seekingalpha.com/news/4099014-moderna-to-seek-parity-for-rsv-shot-as-rivals-lead-in-market","article_id":"2432993572","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1730228397/image_1730228397.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432993572","pubTimestamp":1714672131,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"With its Q1 2024 financials on Thursday, Moderna (NASDAQ:MRNA) highlighted its upcoming RSV vaccine, noting that the company expects U.S. regulators to recommend its messenger-RNA-based shot on par wi","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4501":"段永平概念","BK4588":"碎股","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","MRNA":"Moderna, Inc.","BK7095":"多种金属与采矿","LU0122379950.USD":"贝莱德世界健康科学A2","BK4551":"寇图资本持仓","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4581":"高盛持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999001176.USD":"United Global Healthcare Acc USD","LU1829250122.USD":"高盛欧洲核心股票组合Acc","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4548":"巴美列捷福持仓","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","PFE.AU":"PANTERA MINERALS LTD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","GSK.UK":"葛兰素史克","BK4592":"伊斯兰概念","BK4532":"文艺复兴科技持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","GSK":"葛兰素史克","PFE":"辉瑞","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4139":"生物科技","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC"},"translate_title":"Moderna将寻求RSV疫苗的平价，因为竞争对手在市场上领先","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE.AU":1,"PFE":1,"MRNA":1,"GSK":1,"GSK.UK":0.6},"content_text":"With its Q1 2024 financials on Thursday, Moderna (NASDAQ:MRNA) highlighted its upcoming RSV vaccine, noting that the company expects U.S. regulators to recommend its messenger-RNA-based shot on par with more traditionally developed rival products. Last year, GSK (GSK) and Pfizer (PFE) launched their recombinant RSV vaccines, Arexvy and Abrysvo, after the CDC's Advisory Committee on Immunization Practices (ACIP) recommended the shots to prevent severe respiratory syncytial virus (RSV) infections in older adults. With Moderna's (MRNA) RSV shot, mRNA-1345, under FDA review with a target action date of May 12, the company expects to win U.S. approval for the vaccine in H1 2024, leading to a potentially positive recommendation at an ACIP meeting in June. At the meeting, \"we expect a parity recommendation,\" Moderna's (MRNA) President, Stephen Hoge, remarked during the company's earnings call, citing the data it has already submitted with the marketing application and new data it intends to file. \"We certainly think the data supports that. But again, I'll defer to the committee members on the ultimate decision,\" he added. The Cambridge, Massachusetts-based biotech also highlighted its vaccine's availability as a pre-filled syringe, a key differentiation from rival products which require multiple steps to prepare. \"We believe our PFS presentation for RSV vaccine has the potential to ease the personal burden on pharmacies during the fall respiratory season,\" CEO Stéphane Bancel remarked.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432993572"}